Quantcast

Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories

2008-08-01 06:00:46

Peptimmune has received a US patent which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. Peptimmune's PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the company plans to initiate its Phase II study in relapsing remitting...

2008-07-16 12:01:29

CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's...

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial. Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex. The Bravo trial, which was initiated in April, 2008, aims to enroll approximately 1,200...

2008-07-07 09:01:02

Teva Pharmaceutical Industries has reported results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate 40mg as compared to the approved Copaxone 20mg in the treatment of relapsing-remitting multiple sclerosis. The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favorable safety and tolerability profile of Copaxone 20mg. Approximately 70-80% (78%) of Copaxone 20mg...

2008-07-07 03:00:34

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as compared to the approved COPAXONE(R) 20mg in the treatment of relapsing-remitting multiple sclerosis (RRMS). The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favorable safety and tolerability profile of COPAXONE(R) 20mg....

2008-06-30 12:03:15

Teva Pharmaceutical Industries and Antisense Therapeutics have announced that ATL/TV1102, a novel, anti-sense drug, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis. ATL/TV1102 Phase IIa trial was a randomized, double-blind, placebo-controlled clinical trial of ATL/TV1102. The goal of the trial was to obtain preliminary evidence of ATL/TV1102's effectiveness in reducing multiple sclerosis (MS)-related magnetic resonance images (MRI) brain...

2007-10-12 09:00:10

Data from a 16-year follow-up study of 174 relapsing-remitting multiple sclerosis (RRMS) patients was presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study demonstrates significant clinical benefits on both disability and relapse rates in patients continuously treated with COPAXONE® (glatiramer acetate injection) for an average of 8 years. The majority of patients (84.8 percent) in the ongoing...

2007-05-04 12:00:35

Teva Pharmaceuticals said a combination of Copaxone and antibiotic minocycline reduced brain lesions in patients with relapsing-remitting multiple sclerosis, compared to receiving Copaxone alone. New data from a randomized, double-blind study showed that a combination of Copaxone with the oral antibiotic minocycline reduced T1 Gadolinium enhancing lesions of the brain by 63% and reduced the number of new T2 lesions in patients by 65%. These results trended toward but did not reach...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.